Diagnostic platform for Epstein-Barr Virus (EBV) infection-related cancers and associated autoimmune diseases
There is a global public health need for early diagnosis of Epstein-Barr Virus (EBV) infection-related cancers and for EBV-associated autoimmune diseases. Clinical symptoms associated with these diseases are non-specific, and early detection is difficult.
To solve this problem, the Doolan Laboratory at James Cook University will develop an antigen strip-based or immunoblot strip-based diagnostic platform.
Unique selling point/competitive advantage
The Doolan Laboratory developed a custom protein array, representing all known EBV proteins and variants for cancer biomarker discovery. The research team are able to identify risk signatures that discriminate between cases and controls and identify disease-free individuals harbouring the highest risk for developing infection-related cancers.
Investment or collaboration opportunities
James Cook University is seeking collaborative investment to develop a diagnostic platform, which has the potential to translate into substantial public health benefits for regions affected by EBV infection-related cancers.
Intellectual property rights
The Doolan Laboratory developed a custom protein microarray expressing all known proteins and variants from the Epstein-Barr virus.
Dr Seth Jones
Manager, Development and Commercialisation
Phone: +61 7 4232 1783
Learn about the work of Professor Denise Doolan on this diagnostic tool.
- Last reviewed: 17 Jul 2019
- Last updated: 29 May 2018